Kenya's Kemri begins test kit mass production
This article was originally published in Clinica
Executive Summary
The Kenyan Medical Research Institute, Kemri, has started commercial production of the hepatitis B virus screening kit Kemri HepCell at dedicated new facilities in Nairobi. Kemri has been selling its kits to the ministry of health since 2002, but the decision to begin mass production marks a change in strategy and is designed meet expected growth in demand. It is predicted that Kenya will need around 400,000 HBV tests annually, and Uganda and Tanzania are also showing interest in the product. Currently, imported kits are used to bridge the demand gap not met by the Kemri HepCell kits, which cost around Ksh50 ($0.69), can conduct 200 tests per kit.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.